QualityStocksNewsBreaks Archives

WednesdayNov 30, 2022 12:19 pm

QualityStocksNewsBreaks – Hillcrest Energy Technologies Ltd. (CSE: HEAT) (OTCQB: HLRTF) to Present at Singular Research’s Best of the Uncovered Conference

Hillcrest (CSE: HEAT) (OTCQB: HLRTF), a clean tech company developing transformative power conversion technologies and control system solutions for next-generation electrical systems, today provided a shareholder update on recent activities and announced that it will participate in Singular Research’s Best of the Uncovered investor conference. The 17th annual invitation-only event, taking place in San Francisco on Dec. 8, 2022, is focused on top-ranked emerging growth, undervalued and undercovered companies that exemplify Singular’s research. Hillcrest’s presentation is slated to begin at 12:15 p.m. PT. Investors should register at https://ibn.fm/02VcA to participate virtually. To view the full press release, visit https://ibn.fm/sG9st About…

WednesdayNov 30, 2022 11:16 am

QualityStocksNewsBreaks – MICT Inc. (NASDAQ: MICT) Issues Update on Acquisition of Tingo Inc. (TMNA)

MICT (NASDAQ: MICT) previously announced that it is scheduled to complete the acquisition of the operating business and assets of Tingo (OTC: TMNA) by Nov. 30, 2022. This will be achieved through the acquisition of 100% of Tingo’s sole operating subsidiary, Tingo Mobile Limited. In return, MICT is issuing 19.9% of its common stock to Tingo, together with Series A Preferred Stock and Series B Preferred Stock, each of which are convertible into shares of MICT’s common stock upon satisfaction of certain conditions. “The acquisition of Tingo Mobile will not only make MICT significantly profitable from Q4 2022 onwards,” said…

WednesdayNov 30, 2022 11:07 am

QualityStocksNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Forecasts Accelerated Growth in Coming Year

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), has announced its projected revenue growth for the next 12 months. The company has seen accelerated year-over-year growth, and with the increased interest as well as impressive upswing in signed contracts, Knightscope anticipates tripling annualized revenue. In addition, the company released the first in a series of videos. Titled “Rise of the Robots,” the series is designed to share key company updates with KSCP investors and its tens of thousands of followers. “We’ll be filing the 8-K for the combined entity at the end of the year,” said Knightscope…

TuesdayNov 29, 2022 3:46 pm

QualityStocksNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference

BioRestorative Therapies (NASDAQ: BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that its CEO Lance Alstodt will be participating at the RHK Capital Disruptive Growth Conference. The event is slated to take place in New York City from Dec. 5-6, 2022, and feature leading C-suite executives and senior management of up to 30 growth-oriented and disruptive companies. Attendees will include seasoned institutional and accredited investors, representatives of family offices, market analysts and financial advisors, as well as broker-dealer wealth managers and select RHK clients. Interested parties should visit https://ibn.fm/XMA3b to learn more and submit a…

TuesdayNov 29, 2022 1:51 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD(TM) Demonstrates Enhanced Performance Compared to Leading Anti-Seizure Medication

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that its patented DehydraTECH-CBD(TM) has demonstrated performance enhancements compared to one of the world’s leading anti-seizure medications, Epidiolex(R). According to the update, animal study program EPIL-A21-1 was designed to determine whether DehydraTECH-CBD could provide similar seizure inhibiting efficacy, using an established, vehicle-controlled, acute animal seizure model induced by electrical stimulation (“MES”), at lower doses than were required with Epidiolex, the world’s only commercially approved, CBD-powered anti-seizure drug. In order to minimize adverse side effects, Lexaria is continually searching for the lowest possible efficacious dose levels of…

TuesdayNov 29, 2022 1:34 pm

QualityStocksNewsBreaks – MetAlert Inc. (MLRT), Sensio Group Partner to Distribute 3D Monitoring System – RoomMate(TM)

MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products for remote patient monitoring, today announced its entry into a letter of intent (“LOI”) with Norway-based Sensio Group to begin marketing and distributing RoomMate(TM). A 3D infrared monitoring system, RoomMate is a simple and effective solution for looking after patients without intruding on their personal space. The solution allows for a total “anonymized” supervision and monitoring service using infrared 3D technology with no wearables, cameras or devices needed. “We are very excited about this partnership and remarkable proven technology,” said MetAlert Business Development Director Andrew Duncan.…

TuesdayNov 29, 2022 11:53 am

QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Confirms Inhalation Concept of NanoAb as Therapy for COVID-19

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company today announced statistically significant (p<0.001) efficacy results in a preclinical in vivo proof-of-concept study of its innovative inhaled nanosized antibody (“NanoAb”) COVID-19 therapy. “We are excited that the study results confirm the inhalation concept of our exclusively licensed NanoAb as a therapy for COVID-19 illness. Following these promising results, we intend to continue the study early next year by testing additional dose levels of the inhaled NanoAb therapy and as a prophylactic (preventive)…

TuesdayNov 29, 2022 11:23 am

QualityStocksNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Uncovering Potential for Iska Iska to Become ‘Bonanza Style’ Bolivian Polymetallic Discovery

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) today announced assay results from eight additional diamond drill holes from its ongoing drilling program at the Iska Iska silver-tin polymetallic project in the Potosi Department, southern Bolivia. According to the update, six of the holes (DSB-35 and DSB-37 to DSB-41) tested the south-southeastern extension of the high-grade feeder zone at Santa Barbara while METSBUG-03 is a metallurgical hole drilled from the Santa Barbara adit underground drill bay. DM2-01 is a reconnaissance drill hole near the Mina 2 adit in the southeast section of the property. “Now that the reconnaissance drill holes…

TuesdayNov 29, 2022 10:00 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) 1-for-30 Reverse Stock Split Now in Place

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced a 1-for-30 reverse split of its common stock. According to the announcement, the split was effective at 4:01 p.m. ET on Nov. 28, 2022. Starting today, CNSP common stock will trade on the Nasdaq Capital Market on a split-adjusted basis a new CUSIP number: 18978H201. Approved by company stockholders earlier this year, the reverse stock split is meant to increase the CNSP’s per share trading price and bring the company into compliance with the…

MondayNov 28, 2022 3:33 pm

QualityStocksNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Equity Research Reports

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, was featured in recent equity research reports published by H.C. Wainwright & Co. Titled “Personalizing Precision Immunological Therapy; Initiating at Buy and $4 PT” and “3Q22 Financial Results Reported; Reiterate Buy,” the publications discuss initiation of coverage of Aditxt with a buy rating and 12-month price target of $4 per share. “Personalized COVID-19 analytics can inform vaccinations, treatments and more. AditxtScore determines the coronavirus infection status of an individual, which can help patients and physicians make a variety of…

Site Search

Company Search

Category: QualityStocksNewsBreaks